UBS’s CorMedix CRMD Stock Holding History

UBS’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-103	Closed	-$1K	–	10471
2014 Q1	$1K	Sell	103 -441	-81%	-$5.18K	﹤0.01%	10189
2013 Q4	$3K	Sell	544 -810	-60%	-$3.54K	﹤0.01%	9849
2013 Q3	$6K	Buy	1,354 +1,264	+1,404%	+$5.99K	﹤0.01%	9239
2013 Q2	$0	Buy	+90	New	+$325	﹤0.01%	10174

Other funds holding CRMD

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

GLRA

Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS's CRMD Position: Q2 2014 in Review

UBS sold out of CorMedix (CRMD) in Q2 2014, closing a stake of 103 shares — an estimated $1K sold.

UBS first reported a position in CRMD in Q2 2013 and held it in 4 quarters. The position peaked at $6K in Q3 2013. 12 funds tracked by Wall St. Rank hold CRMD as of Q2 2014.

UBS reported no remaining CorMedix position as of Q2 2014 after selling out during the quarter.
UBS sold 103 CorMedix shares in Q2 2014, an estimated $1K.
UBS first reported a position in CorMedix in Q2 2013 and held it in 4 quarters.
UBS's CorMedix position peaked at $6K in Q3 2013.
12 funds tracked by Wall St. Rank held CorMedix as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.